What is Chemomab Therapeutics Ltd.'s earnings per share (EPS)?

Chemomab Therapeutics Ltd. (CMMB) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a -53.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Chemomab Therapeutics Ltd. (CMMB) Financials

CMMB

FY2025 annual

Net Income -$9.0M +35.5% YoY

EPS (Diluted) $0.02 -53.8% YoY

Free Cash Flow -$11.1M +27.6% YoY

Operating Cash Flow -$11.1M +27.7% YoY

Market Cap $9.5M as of Oct 15, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.8x on $12.3M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 23, 2026 Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 23, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CMMB SEC filings page.

This page shows Chemomab Therapeutics Ltd. (CMMB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score not available

Chemomab Therapeutics Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Chemomab Therapeutics Ltd. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Chemomab Therapeutics Ltd. reported a net loss of $9.0M while operations used $11.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$7.6M

YoY+24.6%

QoQ+38.8%

Chemomab Therapeutics Ltd. held $7.6M in cash as of Q4 2025; long-term debt is not reported for that period.

Shares Outstanding

575M

YoY+52.6%

QoQ+39.0%

Chemomab Therapeutics Ltd. had 575M shares outstanding in Q4 2025. This represents an increase of 52.6% from the same quarter a year earlier. Against the prior quarter it is up 39.0%.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

CMMB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CMMB quarterly income statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Cost of Revenue	$2.3M-5.6%	$2.5M-43.9%	$4.4M-14.6%	$5.1M+55.3%	$3.3M	N/A	N/A	N/A
R&D Expenses	$5.8M-48.5%	$11.3M-38.4%	$18.4M+8.3%	$17.0M+168.0%	$6.3M+35.2%	$4.7M-64.8%	$13.3M+77.0%	$7.5M
SG&A Expenses	$3.7M+9.4%	$3.4M-51.8%	$7.1M-38.8%	$11.6M+91.5%	$6.0M+368.4%	$1.3M-79.4%	$6.2M+13.1%	$5.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$6K-33.3%	$9K-64.0%	$25K
Income Tax	$0	$0	$0+100.0%	-$534K	$0	$0	$0-100.0%	$306K
Net Income	-$9.0M+35.5%	-$13.9M+42.4%	-$24.2M+12.4%	-$27.6M-121.6%	-$12.5M-109.7%	-$6.0M+78.1%	-$27.1M-96.6%	-$13.8M
EPS (Basic)	$0.02-53.8%	$0.04-62.1%	$0.10-14.9%	$0.12+101.7%	$0.06	N/A	N/A	N/A
EPS (Diluted)	$0.02-53.8%	$0.04-62.1%	$0.10-14.9%	$0.12+101.7%	$0.06	N/A	N/A	N/A
Diluted Shares (Avg)	510M+42.1%	359M+52.8%	235M+3.3%	228M+9.7%	207M	N/A	N/A	N/A

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
R&D Expenses	N/A	N/A	N/A	N/A	$2.9M-41.7%	N/A	N/A	$5.0M+72.3%
SG&A Expenses	N/A	N/A	N/A	N/A	$840K-73.5%	N/A	N/A	$3.2M-4.9%
Income Tax	N/A	N/A	N/A	N/A	$0-100.0%	N/A	N/A	$34K+106.3%
Net Income	N/A	-$2.1M+43.3%	-$3.3M+14.1%	N/A	-$3.6M+54.4%	-$3.9M+55.8%	N/A	-$8.0M-28.8%
EPS (Basic)	N/A	N/A	N/A	N/A	$0.01-63.9%	N/A	N/A	$0.04+33.3%
EPS (Diluted)	N/A	N/A	N/A	N/A	$0.01-63.9%	N/A	N/A	$0.04
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	286M+29.1%	N/A	N/A	222M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Interest Expense.

CMMB Balance Sheet

CMMB quarterly balance sheet

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$13.8M-18.6%	$17.0M-23.4%	$22.2M-48.6%	$43.1M-33.1%	$64.4M+415.8%	$12.5M-36.8%	$19.8M+54.8%	$12.8M
Current Assets	$13.4M-16.3%	$16.0M-23.2%	$20.9M-49.9%	$41.7M-33.4%	$62.7M+429.5%	$11.8M-35.0%	$18.2M+66.8%	$10.9M
Cash & Equivalents	$7.6M+24.6%	$6.1M-34.7%	$9.3M-31.3%	$13.5M-11.0%	$15.2M+30.1%	$11.7M-33.6%	$17.6M+133.8%	$7.5M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.5M-56.9%	$3.4M-33.5%	$5.2M-24.6%	$6.8M+136.9%	$2.9M+72.5%	$1.7M-65.5%	$4.8M+63.9%	$3.0M
Current Liabilities	$1.5M-54.1%	$3.2M-33.5%	$4.8M-28.3%	$6.7M+154.7%	$2.6M+101.4%	$1.3M-68.1%	$4.1M+50.1%	$2.7M
Non-Current Liabilities	$0-100.0%	$209K-33.9%	$316K+247.3%	$91K-61.6%	$237K-33.8%	$358K-50.6%	$725K+245.2%	$210K
Total Equity	$12.3M-8.9%	$13.5M-20.4%	$17.0M-53.1%	$36.2M-41.1%	$61.5M+469.0%	$10.8M-12.7%	$12.4M+26.2%	$9.8M
Retained Earnings	-$111.6M-8.8%	-$102.6M-15.7%	-$88.7M-39.0%	-$63.8M-76.4%	-$36.2M-52.7%	-$23.7M+77.5%	-$105.4M-34.6%	-$78.3M

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
Total Assets	$13.8M-18.6%	$11.1M-23.5%	N/A	$17.0M-23.4%	$14.5M-49.6%	N/A	$22.2M-48.6%	$28.8M-48.8%
Current Assets	$13.4M-16.3%	$10.6M-21.1%	N/A	$16.0M-23.2%	$13.5M-51.4%	N/A	$20.9M-49.9%	$27.7M-49.5%
Cash & Equivalents	$7.6M+24.6%	$5.4M+8.2%	N/A	$6.1M-34.7%	$5.0M-51.5%	N/A	$9.3M-31.3%	$10.4M+5.0%
Short-Term Investments	$0	$0	N/A	$0	$0	N/A	$0	$0
Long-Term Investments	$0	$0	N/A	$0	$0	N/A	$0	$0
Total Liabilities	$1.5M-56.9%	$1.4M-68.6%	N/A	$3.4M-33.5%	$4.6M-33.5%	N/A	$5.2M-24.6%	$6.9M+51.0%
Current Liabilities	$1.5M-54.1%	$1.4M-66.8%	N/A	$3.2M-33.5%	$4.3M-36.9%	N/A	$4.8M-28.3%	$6.8M+55.3%
Non-Current Liabilities	$0-100.0%	$0-100.0%	N/A	$209K-33.9%	$251K+660.6%	N/A	$316K+247.3%	$33K-77.7%
Total Equity	$12.3M-8.9%	$9.7M-2.9%	$10.4M-22.0%	$13.5M-20.4%	$10.0M-54.6%	$13.3M-52.3%	$17.0M-53.1%	$22.0M-57.6%
Retained Earnings	-$111.6M-8.8%	-$108.0M-12.3%	N/A	-$102.6M-15.7%	-$96.2M-19.4%	N/A	-$88.7M-39.0%	-$80.5M-69.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CMMB Cash Flow Statement

CMMB quarterly cash flow statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$11.1M+27.7%	-$15.4M+34.8%	-$23.6M-15.9%	-$20.4M-64.6%	-$12.4M-136.1%	-$5.2M+68.1%	-$16.5M-15.7%	-$14.2M
Depreciation & Amortization	$70K+32.1%	$53K-20.9%	$67K+15.5%	$58K+70.6%	$34K+41.7%	$24K-91.5%	$281K+325.8%	$66K
Stock-Based Compensation	$623K+1.0%	$617K-58.6%	$1.5M-53.6%	$3.2M+59.0%	$2.0M+1453.1%	$130K-88.8%	$1.2M-39.9%	$1.9M
Capital Expenditures	$3K	$0-100.0%	$3K-95.6%	$68K-71.5%	$239K+528.9%	$38K-60.0%	$95K-55.4%	$213K
Free Cash Flow	-$11.1M+27.6%	-$15.4M+34.8%	-$23.6M-15.5%	-$20.4M-62.0%	-$12.6M-138.9%	-$5.3M+68.1%	-$16.6M-14.7%	-$14.4M
Investing Cash Flow	$5.4M+134.7%	$2.3M-85.5%	$15.9M-18.7%	$19.5M+143.2%	-$45.2M-72780.6%	-$62K+34.7%	-$95K+55.4%	-$213K
Financing Cash Flow	$7.2M-27.5%	$9.9M+181.6%	$3.5M+533.7%	-$808K-101.3%	$61.1M+1185.8%	$4.8M-82.2%	$26.6M+29.1%	$20.6M

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$7.5M-31.3%
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$16K+14.3%
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K-81.8%
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$7.5M-31.1%
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$4.3M-347.1%
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.4M+6118.2%

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

CMMB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CMMB quarterly financial ratios

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Return on Equity	-72.9%+30.1pp	-103.0%+39.5pp	-142.5%-66.2pp	-76.3%-56.0pp	-20.3%+34.8pp	-55.1%+164.1pp	-219.2%-78.5pp	-140.7%
Return on Assets	-65.1%+17.1pp	-82.2%+27.1pp	-109.3%-45.1pp	-64.2%-44.8pp	-19.4%+28.3pp	-47.7%+89.6pp	-137.3%-29.2pp	-108.1%
Current Ratio	9.08+4.1x	4.98+0.7x	4.32-1.9x	6.18-17.5x	23.66+14.7x	9.00+4.6x	4.42+0.4x	3.98
Debt-to-Equity	0.12-0.1x	0.25-0.1x	0.30+0.1x	0.19+0.1x	0.05-0.1x	0.15-0.2x	0.39+0.1x	0.30

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
Return on Equity	N/A	-21.2%+15.1pp	-32.0%-2.9pp	N/A	-36.4%-0.1pp	-29.0%+2.3pp	N/A	-36.2%-24.3pp
Return on Assets	N/A	-18.5%+6.5pp	N/A	N/A	-25.0%+2.7pp	N/A	N/A	-27.6%-16.6pp
Current Ratio	9.08+4.1x	7.42+4.3x	N/A	4.98+0.7x	3.12-0.9x	N/A	4.32-1.9x	4.06-8.4x
Debt-to-Equity	0.12-0.1x	0.15-0.3x	N/A	0.25-0.1x	0.46+0.1x	N/A	0.30+0.1x	0.31+0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Chemomab Therapeutics Ltd. CMMB	FY2025	N/A	-$9.0M	N/A	$9.5M	—
Tharimmune, Inc. THAR	FY2025	N/A	-$35.9M	N/A	$187.4M	—
Longeveron Inc. LGVN	FY2025	$1.2M	-$22.7M	N/A	$4.8M	44/100
Minerva Neurosciences, Inc NERV	FY2025	N/A	-$293.4M	N/A	$115.5M	—
Cocrystal Pharma, Inc. COCP	FY2025	N/A	-$8.8M	N/A	$19.8M	—
Edesa Biotech, Inc. EDSA	FY2025	N/A	-$7.2M	N/A	$25.7M	—

Where Chemomab Therapeutics Ltd. Ranks

Frequently Asked Questions

Is Chemomab Therapeutics Ltd. profitable?

No, Chemomab Therapeutics Ltd. (CMMB) reported a net income of -$9.0M in fiscal year 2025.

What is Chemomab Therapeutics Ltd.'s return on equity (ROE)?

Chemomab Therapeutics Ltd. (CMMB) has a return on equity of -72.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Chemomab Therapeutics Ltd.'s free cash flow?

Chemomab Therapeutics Ltd. (CMMB) recorded an outflow of $11.1M in free cash flow during fiscal year 2025. This represents a 27.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Chemomab Therapeutics Ltd.'s operating cash flow?

Chemomab Therapeutics Ltd. (CMMB) recorded an outflow of $11.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Chemomab Therapeutics Ltd.'s total assets?

Chemomab Therapeutics Ltd. (CMMB) had $13.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Chemomab Therapeutics Ltd.'s capital expenditures?

Chemomab Therapeutics Ltd. (CMMB) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Chemomab Therapeutics Ltd. spend on research and development?

Chemomab Therapeutics Ltd. (CMMB) invested $5.8M in research and development during fiscal year 2025.

How many shares does Chemomab Therapeutics Ltd. have outstanding?

Chemomab Therapeutics Ltd. (CMMB) had 575M shares outstanding as of fiscal year 2025.

What is Chemomab Therapeutics Ltd.'s current ratio?

Chemomab Therapeutics Ltd. (CMMB) had a current ratio of 9.08 as of fiscal year 2025, which is generally considered healthy.

What is Chemomab Therapeutics Ltd.'s debt-to-equity ratio?

Chemomab Therapeutics Ltd. (CMMB) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Chemomab Therapeutics Ltd.'s return on assets (ROA)?

Chemomab Therapeutics Ltd. (CMMB) had a return on assets of -65.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Chemomab Therapeutics Ltd.'s P/E ratio?

Chemomab Therapeutics Ltd. (CMMB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $9.5M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Chemomab Therapeutics Ltd.'s price-to-sales ratio?

Chemomab Therapeutics Ltd. (CMMB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $9.5M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Chemomab Therapeutics Ltd.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Chemomab Therapeutics Ltd. (CMMB) held $7.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $11.1M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Chemomab Therapeutics Ltd.'s Piotroski F-Score?

Chemomab Therapeutics Ltd. (CMMB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Chemomab Therapeutics Ltd.'s earnings high quality?

Chemomab Therapeutics Ltd. (CMMB) reported a net loss of $9.0M while operations used $11.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.